Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors

Abstract

The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely severalfold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.